-
2023-505283-11-00
6
2024-12-10
Relapsing forms of Multiple Sclerosis (RMS)
-
2024-516874-31-00
5
2024-12-10
Patients with a low-grade serous epithelial carcinoma of the ovary (LG
-
2022-501095-25-01
5
2024-11-04
Pediatric Subjects with Infantile-onset Pompe Disease Aged 0 to < 18 Y
-
2023-509877-22-00
5
2024-10-30
severe von Willebrand Disease
-
2023-507637-19-00
3
2024-10-15
Small Lymphocytic Lymphoma
-
2023-506602-39-00
6
2024-08-01
schizophrenia, schizoaffective disorder, schizophrenifom disorder
-
2023-508099-12-00
5
2024-06-20
Dermatitis atopic
-
2023-503904-10-00
5
2024-06-07
Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
-
2023-507039-39-00
5
2024-03-22
Moderate to Severe Plaque Psoriasis
-
2023-509885-39-00
5
2024-01-15
Tuberculosis
-
2022-501980-42-00
5
2023-12-21
Anemia associated with Chronic Kidney Disease
-
2022-501882-29-00
5
2023-11-03
Generalized Myasthenia Gravis (gMG)
-
2023-505140-19-00
5
2023-07-31
Childhood Idiopathic Nephrotic Syndrome
-
2022-500273-14-00
10
2023-07-17
Atherosclerotic cardiovascular disease in patients with ESKD
-
2023-503322-39-00
3
2023-06-16
Newly diagnosed patients with metastatic (other than lung/pleura metas
-
2022-500718-24-00
5
2023-06-09
IgG4-Related Disease
-
2022-500609-42-00
4
2023-02-24
Anemia Due to Lower-Risk Myelodysplastic Syndromes
-
2023-505277-32-00
5
2023-01-26
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2022-500391-62-00
9
2023-01-19
Subjects with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL
-
2023-507031-38-00
5
2023-01-09
Severe viral lung infections
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2022-500367-12-00
5
2022-11-30
Dermatomyositis
-
2023-506548-18-00
10
2022-11-10
Dermatitis atopic
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan